Cdk4/6 inhibitors and overall survival: power of first-line trials in metastatic breast cancer

Palbociclib, ribociclib, and abemaciclib have been investigated in combination with aromatase inhibitors as first-line therapy for metastatic hormone receptor-positive breast cancer (PALOMA-2, MONALEESA-2 and MONALEESA-7, MONARCH-3 trials, respectively); pivotal trials led to absolute median progres...

Descripción completa

Detalles Bibliográficos
Autores principales: Tanguy, Marie-Laure, Cabel, Luc, Berger, Fréderique, Pierga, Jean-Yves, Savignoni, Alexia, Bidard, Francois-Clement
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Perspective
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6018749/
https://www.ncbi.nlm.nih.gov/pubmed/29951582
http://dx.doi.org/10.1038/s41523-018-0068-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6018749/
https://www.ncbi.nlm.nih.gov/pubmed/29951582
http://dx.doi.org/10.1038/s41523-018-0068-4

Ejemplares similares